Author

Carole Marcillat

Institution: Roche (Switzerland)

Observed institution: Roche (Switzerland)

OpenAlex ID: A5045915531

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (S36.001)

2018 · Stephen Hauser, Ludwig Kappos, et al. · Neurology · 5

Safety of Satralizumab Based on Pooled Data from Phase 3 Studies in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) (1281)

2020 · Benjamin Greenberg, Jerome De Seze, et al. · Neurology · 3

Long-term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (S5.001)

2023 · Anthony Traboulsee, Ingo Kleiter, et al. · Neurology · 1

Long-term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Phase 3 SAkuraSky and SAkuraStar Studies (S25.010)

2022 · Benjamin Greenberg, Jerome De Seze, et al. · Neurology · 1

Long-term Safety of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (P13-5.002)

2023 · Brian Weinshenker, Michael R. Yeaman, et al. · Neurology

Works count: 5

Citation count: 10

H-index: 2

I10-index: